Aromasin is a medication, specially formulated to treat estrogen receptor-positive breast cancer in women who have gone through the menopause. Estrogen receptor-positive breast cancer is a type of cancer which is influenced by the hormone estrogen. Aromasin is categorized under the drug class Aromatase inhibitors that work by blocking the aromatase enzyme, which is required by the body to produce estrogen. The tumour is less able to grow in the presence of low levels of hormones. The breast cancer medication was approved by the US FDA to prevent cancer recurrence in postmenopausal women. It is also useful in treating cancer of the advanced stage that has progressed despite tamoxifen treatment. Women with oestrogen negative breast cancer and those who are at their premenopausal phase should not use this medicine, and they should consult their doctors for other effective solution.  The drug extends the survival rates of women who have estrogen-positive breast cancer. Despite its effectiveness in preventing breast cancer recurrence and increased survival rate, Aromasin carries specific side effects, including bone loss and fetal harm.

Benefits of Aromasin

How Aromasin works?

Aromasin reduces the amount of estrogen hormone in the body.  Estrogen receptor-positive cancers are stimulated to grow by estrogen. Before the menopause, estrogen is produced in the ovaries of women. After the menopause, woman’s ovaries are no longer to produce estrogen, but a small amount is produced in body fat. Here aromatase enzymes play a crucial role.  Being an aromatase enzyme, Aromasin stops the enzyme from working, which means there’s less estrogen in the body that supports breast cancer growth.

The medicine is suitable for postmenopausal women and women who have estrogen receptor-positive breast cancer. With the help of a tissue sample test, a woman’s hormone receptor status can be identified. The test will help you find the number of receptors for estrogen or progesterone in breast cancer cells. Aromasin is currently the most effective solution when it comes not treating breast cancer.  It can be included to prevent cancer recurrence after primary cancer treatment (tamoxifen therapy). The medicine can also be given to women with advanced-stage breast cancer that progresses after tamoxifen therapy. In such cases, Aromasin can be used in place of tamoxifen, note that these drugs should not be consumed together. Please consult your doctor if you have any doubt. When it comes to the dosing regimen of Aromasin, the usual dose is 25 mg once daily immediately after a meal. The medicine absorbs fat and is less able to do so on an empty stomach. Generally, the dose will depend on an individual’s condition. Usually, it is taken for five to ten years. In some cases, the doctor asks the patient to start taking breast cancer medication after a few years of taking tamoxifen n drug. If you may be receiving it to prevent cancer recurrence or treating the disease of the advanced stage, then you may usually need to take it for a more extended period to keep the cancer growth under control.

Your doctor will tell you when to stop the treatment until you need to take it regularly to prevent breast cancer growth. You are not allowed to discontinue it without your doctor’s permission. A lot of patients receiving Aromasin therapy worry about stopping the treatment, but if clinical data is to believe continuous use reduces the risk of cancer recurrence for many years. Furthermore, not taking medicine for the prescribed duration may put you at increased risk f cancer recurrence. If you wish to discontinue the treatment, then speak to your doctor. Sometimes your doctor can change the treatment to another hormonal tablet. When it comes to treating breast cancer, hormone therapy is considered as a secondary treatment choice. If Aromasin stops working, your doctor may ask to take another hormonal drug.  If you have any doubt regarding the use of medicine, you can consult your doctor.

Aromasin is the adjuvant treatment of women with estrogen receptor-positive cancer that has been dominated the breast cancer treatment for decades. A switch to this anticancer medication after 2 to 3 years of tamoxifen therapy is associated with a survival benefit. The drug works by lowering circulating oestrogen concentration in the body.